2025 ICD-10-CM code C92.1
Chronic myeloid leukemia (CML) characterized by the presence of the BCR/ABL gene.
Diagnosis of CML requires demonstrating the presence of the BCR/ABL fusion gene or the Philadelphia chromosome, which is the defining characteristic of this type of leukemia. The medical necessity for treatment is based on the disease phase, symptoms, and potential complications like infections, anemia, and bleeding problems.
Physicians diagnose CML through physical examination, blood tests (CBC, peripheral smear, blood chemistries, coagulation studies), bone marrow biopsy or aspiration, and sometimes lumbar puncture.Further tests like flow cytometry, PCR, FISH, and genetic analysis confirm the diagnosis and subtype. Imaging studies such as CT, MRI, PET scans, and ultrasound may also be used for staging and monitoring. Treatment generally involves chemotherapy, targeted therapy, and potentially stem cell transplantation.Radiation therapy and surgery are used less often.
In simple words: Chronic myeloid leukemia (CML) is a type of blood cancer where your bone marrow makes too many abnormal white blood cells.It happens because of a specific gene problem called the BCR-ABL gene, which makes the cells grow out of control.
Chronic myeloid leukemia (CML), BCR/ABL–positive, is a type of cancer that starts in the blood-forming cells of the bone marrow. It is characterized by the presence of the Philadelphia chromosome, a genetic abnormality where parts of chromosomes 9 and 22 swap places, creating the BCR-ABL fusion gene. This gene produces a protein that causes uncontrolled growth of white blood cells, leading to CML.
Example 1: A 55-year-old patient presents with fatigue, night sweats, and an enlarged spleen. Blood tests reveal elevated white blood cell counts.Genetic testing confirms the presence of the BCR-ABL gene, leading to a diagnosis of C92.1., A patient with CML in the chronic phase, monitored through regular blood tests, shows an increasing number of blast cells (immature white blood cells).This progression towards the accelerated phase necessitates a change in treatment strategy, although the code remains C92.1., During a routine check-up, a complete blood count (CBC) shows an abnormally high white blood cell count.Further investigation reveals the Philadelphia chromosome and the BCR/ABL fusion gene, confirming CML, even though the patient is asymptomatic at this stage (chronic phase C92.1).
Complete blood count (CBC) results showing abnormal white blood cell counts, bone marrow biopsy or aspirate findings, cytogenetic analysis demonstrating the Philadelphia chromosome and/or BCR-ABL fusion gene, and molecular testing results confirming the BCR-ABL-positive status.
- Specialties:Hematology, Oncology
- Place of Service:Office, Inpatient Hospital, Outpatient Hospital, Independent Clinic, and other places providing diagnostic and treatment services for CML.